KRMD - Earnings call transcript Q4 2021 | KORU Medical Systems, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings. Welcome to KORU Medical Systems Fourth Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation . [Operator instructions] Please note, this conference is being recorded. conference your the Greg turn now over host to Chodaczek. I'll

begin. may You

Greg Chodaczek

full XX, Shamali Earlier press for financial and everyone. good release the ended KORU quarter Thanks the afternoon, released is today, available and company's of A XXXX. copy Medical on Systems fourth year the December website. results

Actual other could the most and we are update well you, our based financial SEC. any comments the materially will call, the commentary release statements expectations this many release uncertainties, These of to certain forward-looking associated risks to results regarding I which including We includes in on our matters. statements. press press of predictions events listeners our encourage and recent filings due as to During those quarter. make business front as differ forward-looking obligation results as today. plans or and and have on our assume no our with in mentioned

non-GAAP our which are management our and the of will each During accompanying and SEC, website. our filings measures presentation press financial discuss posted the Investor in release with call, certain in on

release comparable will measures reconciliations of the measures, additional in disclosure including filings. You measures presentation with our regarding non-GAAP these and investor find these and press those accompanying GAAP

For most related additional and reference with recent please Eastern the Time. made then topics this recorded benefit Since company's XXXX SEC. have replay, of approximately the and held those comments PM X:XX press listening company discussed, filings on was the XX, call to the the at Wednesday, March to the releases and may

Chief CEO Karen of is please today call and Tharby, Financial KORU KORU's Officer. Systems; Medical ahead. Linda, the and President go Fisher, on us Joining Linda

Linda Tharby

and Medical welcome Good afternoon, full Greg. fourth quarter you, and to XXXX earnings call. year Thank KORU everyone, Systems

year, the to our by incredible would from like reviewing QX XXXX start thanking highlights our I team. Before

a quarter, delivered are then and will ending and by and patient's an Karen call I a each over delivering individuals of be life and growing Karen After review Medical is update prepared group to I up I'll foundation developing highlights, comments. the remarks, for improve QX few upon strategic and ourselves slide be and who guide turn discuss we are I to fourth closing is brief by Systems to an use happy positioning and company build therapeutic overview will quarter XXXX our yearend solutions then milestones begin in overview financials. wanted guidance with our we'll continue our today the quarter of into our followed our Prior drug KORU quality our delivery in a hard talented home. mission to and deck supported with for of we using shareholders. high Medical Each remarks. who during begin by quality we Our on today believe the organization value to to continued KORU will individual's quarter. a our a due work. how deliver to dedication of stronger Today, before and to highlights to the I the customers to continued call our Q&A. open jumping with to

treatment XX,XXX via or subcutaneous to treatments at over system. Medical immunoglobulin patients Freedom enabled receive have We leading home SCIg infusion market KORU

on indications XX with in and partnership model proven We countries. have over our registrations commercial system Freedom pharma over infusion XX a drugs and

to we foundation grow have our continue build. which a can we As we scalable business, from

partners our by consumables specialty We to have patients their a supported revenue stream pharmacy in deliver our monthly home. who recurring

$X today drugs billion and pipeline our broader KORU intent market into the goal market. penetration our to per from the to delivery is a home continue As add subcu $XXX to we expand. IG overall expand new to growth as look our our the drugs in Further, the over therapy in of addressable to system their to continued is through million subcu future, total

Medical continue large and drug as premier to KORU platform will at the solidify We our position company. as volume SCIg home delivery a infusion leading home, establish further market infusion

forward we growth our adjusted revenues results momentum. I the intended held of the for drive a vision On company international to for of value of market that on to XX% initial we the or This reiterate sequential of level discussed growth. want of businesses, this outperforming and stocking. and continuing the we fourth and therapy In was return an three XXXX in US Turning and related due growing fourth to revenues for recorded note are growth core novel new basis, important The our market, business digit our look our consecutive to vision. growth December, a new to increase quarter Investor fourth million, had we out on reported domestic double with in quarter, Well, pump by the and net for core through underlying for XX% growth market milestones we and outpacing subcue core, an positive agreements to quarter therapies. growth $X.X Day to core our pipeline. is overall therapies in basis XXXX XXXX, year novel the creation. domestic key of represents rolled plans digit year wins the our it strength we to this year across phase consumables quarter don't to expect IG all we year driven markets an next international each double and higher

and quality being home revenue strong a from leader we million billion as large approximately delivery. a market a $X over will support infusion generate need is of to in XX year, to Our $XXX we being on biopharmaceutical bringing innovation our $XX five-year to in in this from foundation and to move US development. subcue headcount to better We large total and year and work leader that addressable in great plan new XXXX regulatory did designed in therapies hired a subcue even this build commercial building standards much an market know over our capabilities volume We research specific our the novel and larger IG million beginning XX to foundation for on drug and and we out focus build volume employees vision, the in excellence, our to with a particularly importantly, sales drive and over by marketing to company.

become production outsource our location prime our year and in for dual enabling center excellence of progressed securing recruiting source improvement. future a in also will We new New Jersey we driving ended a of And agreement, Northern margin growth products. new facility manufacturing a the a that

driven therapies. pillars be including that subcutaneous will plan position of leadership Our new novel extending penetration increasing and by into infusion two growth, core SCIg home

is total today than around with SCIg IG in The in administered XX% focused the first is We accelerating penetration drugs participate less market. today. of This our delivered pillar under penetrated significantly market subcue.

this area new of focus patient on first The area in is starts.

We efforts. detailing are our pharma our drug gain increased physician clinical building approval process and to on their regulatory recently their our partners our regulatory we of receives through label and training with partners to approval, increasing level work begin development and indications. our have pharma funnel, support the Once the

We months their second introduction of XX prefills area since see Prefills growth The their about patient. target convenience represent grown SCIg because is in X.X% and tremendous rapidly now ago the total for about prefills. of potential have market. the

our have drug to ex-US subcue we see define As label US efforts our further core seen in you'll -- expand, international XXXX strategy.

novel delivery position to into development. our subcue extend our second pillar leadership goal growth, and IG our Turning subcue new of therapies, drug drugs in is to our

all three Our team has spans identified clinical that list trial a phases. robust target

We over in are to XX those MLs. been close development have a a new as X,XXX of identified drugs hundred targeting established has volume whose and roughly

by projecting line drug with large towards goal. our XXXX have by additional phase three new candidates one new XXXX are commercialized and five volume to drive top We five-year through assumed KORU growth Medical we going trials drug

We record continue drug our with satisfaction, our factor momentum broad handle track as to drugs profile build form to and to XX of partner over regulatory safety capability patient MLs, clearances. delivery due a

investment success support to is and as capability infusion our We strategic is major have product the a specialty channel approval drug This areas patients. simplify renewed our of improvements, can focus the a on all opportunities improving both and these for with we improve convenience Innovations through Underlying for the define ensure in focus the the of process the our to pharmacy innovation. we on relationships. extensions and proven and area comfort for line company, through patients. process infusion of include

in qualities further and we convenience core as infusion a and capabilities such generation next system freedom retain will investing are that add system improve connectivity. Additionally,

initiatives. executing progress we have the in to our transition let's on strategic QX Now and made

use FDA us. of format. FDA indications. achieved we on-label step driver on-label convenience in received potential In to pump XXX essential to fourth considerable clearance two syringe for infusion Hizentra the committed XXXX this pre-filled syringes. significant the penetration SCIg November, its of the forward. happy used Octapharma's The pillar drugs to prescribed Edge pre-filled clearances an be market. for be the FREEDOMXX critical to a it The Freedom in and the clearance on-label and available first driver December, in the FDA additional SCIg Cutaquig product, In infusion use an infusion having for for ml significant a system syringe the faster FDA and is of increasing drugs; pre-filled that clearance XX three our Freedom K Regarding indications milestone additional making will market a for received as on-label has Hizentra XXX-K is growing allows report and market penetration, due growth Xembify. system quarter, with to is our XX we two the This to be us and a clearance SCIg before that we end of partners as I'm the for new company most device late first [ph] the

for in FDA promote and by have research review team. clearances FREEDOMXX to gives and customers, drugs capabilities an In to are They to We're believe EU total [indiscernible]. demonstrate these three partners Having which expect had the [indiscernible] vision. clinical indication addition, hit we green new light year eight us for end strong label made in leadership be advantage. these indication a commitments QX, regulatory to cycle five the we our of the and the of XXXK and label excited development XXXX to drug on and for of QX our we our the considerable the

to pillar we advancements have of novel growth, therapies, made second our Regarding significant our pipeline. expanding

earlier with trials of agreement of During our the the of agreement closed closed therapies and expanding agreements phase in subcue in areas and services. closed therapies, of based novel We two for supporting agreements. XXXX, a with therapies. therapies are with upon for are or drug novel new two four an current therapy Three for Among increased future novel exchange first phase an strategy, define immunoglobulin. as of in penetration agreements, focused on immunology we current, are and with area beyond agreements revenues IG the three trials things for note our SCIg In we expanding non trials drugs. immunology oncology products fourth quarter new our and respiratory we four new line are

agreements of we Second in finally have pipeline. new six is the that XX four are our opportunities and quarter occurring have pace secured we in improvement with over four pursuing our we

and strategy pipeline and creation expansion, KORU of as of look excited at products continue on term short our value milestones to addressable well objectives, new, as remain mature to forward about we market As next opportunities we a expand clear progress total services. set commercial the and and goals, reporting phase a will is Medical. for and on both With fairly begin

existing we and our pathway a have we initiative Within brand and the business, strength on innovation areas. to believe growth execute of strategic

now continue to market. updating the leadership review delivery of excited Karen our it home in as for milestones extend will over subcue we to turn are We position financials. drug our our I

Karen Fisher

Thank good you, everyone. and afternoon, Linda

of growth Selling, XX% XX.X% year, million could in with infusion Medical driven Novel core or by primarily net XX I'm our administrative on investments prior companies business into consumables primarily the everyone revenues plan same represent to freedom -- KORU from expand XXXX, novel the core product support system revenues The engineering to support XX.X% strategic reminder, fourth Each and in build increase stocking our $X sales were at last XXXX primarily with core revenues in areas. development. fees a grew cleared of our and and process, feasibility growth and commercial the of and compared by regulatory well fourth novel therapies core, for period for consist and in consumables, period subsequent driven therapies for development a last the international in drug consist for revenues KORU agreement quarter discussion was net revenue therapies $X.X reported increase revenue commercialization XXXX pipelines. XX% that of year, I'm our our will non-recurring increases. specialty pipeline by compared quarter last XXXX. of business, the consulting fourth of of sales new driven all As revenue. financials, by same driven as product revenues quarter I inventory customers driven and clinical in by our fourth was of business service pleased areas, to to for and Medical for on quarter infusion defines strategy. our to core biopharmaceutical report increased development, the in sales international these expenses QX increased areas The ready remind domestic to quarterly the revenues support of all and with and the domestic we XXXX an customize general as use new net Gross development quarter increased associated therapies. was key drugs $X price net X% increase headcount Once sorry, $X.X execute of cleared the increased three novel Sequential clinical to as to signed fourth or pumps year. million Research use. core potential therapies three and be want commercialization, to expenses for million a international prior core. are margin quarters. trials from million, of XX.X% as by system. product year driven of and Adjusting

loss we to per quarter internal innovation was fourth our $X.X share have foundation in fourth diluted initiatives on Gilero of negative diluted XXXX our in capabilities. quarter per our by in for engaged previously share $X.XX As development $X.XX efforts loss order Net line building reported, just build we as expedite while or The investments million described. with driven our XXXX. the they and strategic in was execution our of the

year. order there increase net International $XX.X year-over-year were novel For revenues year. in in net core mostly were new the growth driven year to was the XXXX in for customers. last second year, XXXX, The in trial by than the by lower clinical shortfall with compared full million revenues were driven X.X% up year, XXXX. the of higher net large revenues driven $XX.X X.X% by a million, lower core Domestic XX.X% prior was as compared the price last half therapies

XX.X% the the manufacturing and The half compared primarily offset in in second year XXXX. full secondary driven delays by For of source year. gross XXXX, product was price in to favorability by margin to decrease a mix XX.X% the was transition

and increase the novel the our last general or same million primarily period is XX.X% expenses commercialization support investments to to business $X.X to year. development compared increased in For full selling, This team year therapies. administrative due and for XXXX,

our For increased internal we Gilero to XXXX, full with period communicated development last million our related expenses expedite while innovation engagement reflecting and prior build year the order with efforts expenditures $X.X research capabilities. development our compared year, in to same innovation

negative efforts. it foundation, closing product XXXX, investments decrease $X.XX per back expand of will now full for per $X.X development XXXX by share diluted from the net to comments. and For in loss Linda and driven period innovation I turn diluted to million over X% a year and was guidance same our commercialization or share our

Linda Tharby

Thank you, Karen.

the outlook for digits. XX continued activity in the key chain starts, XXXX, several to high trial reflecting drivers growth plasma our patient Turning underlying market related SCIg reflects recovery to from market we the expect grow Currently expectations and single recover impact. new COVID and SCIg fiscal pandemic clinical supply to supply

closing Assuming agreements, or to including XXXX. that business continue in $XX in range digits, XX% XX% to therapy this and the market revenues our the grow in million mid of the low outpace new $XX target full we core we US of growth believe to for growth, multiple will novel year double a guiding IG where to the market million

to the on slower late impact diagnosis expect between Omnicom QX therapy QX market US days. new due Freedom in start of starts We XX the in XX from as start the and take to patient to core could

of that at to $XX and to to line year our transition the three completed growth, expect gross we exit roughly the rate operating expenses support increase run the secondary to begin our reiterating initiatives our for as million In be are quarters in We with to line $XX first top to expect XXXX. the full year we margin XXXX guidance plan XX% and time. drive XXXX, roughly to source order strategic million to to

investment includes expense our deals, expanding innovation generation additional of our on our non-IG next goals term TAM pipeline, initiatives product. therapy securing continued Freedom of new including building development with operating novel our Our near through and in strategic our system advancements

expect quarter. You hold a that then consistent XX% XX% run to QX XXXX to of we will rate can off finished fairly quarter where

capitalized XXXX Looking our that XXXX. to strategic $XX.X at compared continue at And as to to year plan. drive value we balance in with end execute $XX.X sheet, ended cash million million we our we we are believe on well

efforts of includes and new selling investments which innovation efforts to to our commercial remainder facility. We and marketing, our foundation, regulatory the with in in between our split expect be growth drive majority the and in through investment EUMDR being strengthening in

forward XXXX, milestones to execution we as strong digit to Medical I'm KORU expanded We of and monitored we over closing, full the hit now team. our the as proud and in continued objectives to novel We our with to set strong providing it the pipeline, as in We In company several look continue Q&A are Shamali and of you. initiative stop growth. place at disciplined forward of XXXK made on approach added double in the will for remain our progress be additional that drive I plan. reflected finish. year And as Thank in our we look and clearances, very funds updates therapies deployment turn fourth back back We operator multiple going strategic to fourth milestones. will a returned our build the to we achievable quarter incredibly quarter and our new gates advancements confident we

Operator

[Operator instructions] line And Matt Piper with Sandler. our your with first on of the question comes question. Please O'Brien proceed

UnidentifiedAnaylst

here. bit digit that that with be of are the then double would afternoon. want to you some single it This What is the maybe QX off over on on market, to towards what to start folks the number do the just the good year factors digit taking think on off are your assuming for I Thanks a questions perspective, pointing market for subcue, here. Drew have little transition to KORU. on nice for guidance, March mid congrats I growth solid just years, it we could and COVID, be on influenced high digits points growth data the end Matt. high market color Hi, Maybe be from COVID you the on low rate? for last using a single triangulate start a to and couple the

Linda Tharby

Sure.

there. lot was There a So for the Drew, thanks in question.

me me try So try and and unpack that. let let

So over market you a basis which fourth we overall quarter, what about that know, let's by just but into the quarter on track which grew we marketplace. versus encouraged full in saw total are market fourth X% And we three. subcue saw the that delivered the is drug IG the quarter grow X% start year as with

about our January of a four start is that that in days. So XX latter that and look Omicron said to of quarter is Having from to the months what is happens generally patients be as experienced at in we in market, think hangover XX encouraging. the we we diagnosis from early going indications time all of time to there's slight

start particular. to a but out the the little digits double So of XXXX market we in slower project we're business, US gates versus for at our bit of start still a going in

I So would being ended quarter growth. one where project double we a digital

Did I I got I I drew? did miss everything. think anything? Karen miss

UnidentifiedAnaylst

Nope, that was perfect. Thank you.

Linda Tharby

you We conversions, that market look there. in one Obviously there thing at growth, look sorry. what Appell about. Maybe to subcue lot we into a is commercialization. that syringe, asked, we at talked I on is get look assumptions but the There you got we at number that there, prefilled of they go went

UnidentifiedAnaylst

the street, to they're the just this in road? drive to start where pipeline, in guiding Is just Perfect. side, up spend going those a those you probably in allocated. the paying looks step is dividends little Very be helpful. more are a then to the being next sales the like us there therapies a couple here down novel Maybe going understand, could out it focus where OpEx and about And bit on on XXXX. years of feet really year you're to on larger think building how should dollars we help

Linda Tharby

Yeah.

first say the some see it term and improvements. So you've would started is to already short of I

first So we commercial significant made capabilities. some our in investments

some that starting in to growth team see US in marketing turned So the we we market. people you're in teams, the that over and our already US and new QX of our added and sales recorded impact

four Second people drive being saw novel area new couple we again our four. secured is for in a agreements to and added really you to of quarter commercialization team therapies

of start term to and see it some So is short you'll that.

in several that regulatory experience the we in and occur and function expertise you and again, in first years. added significant is new company saw three for quality on-label The the our indications area other

see into are bit investments. So other I'll are get the then which And impact term term, be a R&D longer spends, which short our you're there. little to starting some to going

this company not was at. run company a was So see the I money rate in area. a really that million When the you the under of tested investments, looking our can had dollars R&D not lot say lot a

patient that from innovate satisfaction dollar open basis capture starting need here the that to on need and we That's dollar up addressable we're a billion billion today, to to we pipeline, connected. convenient great product, therapies for we need to we're make a going us pipeline. it plus really make novel to to really have and more it high going plus that So low product

move. So some investments R&D in We're just then breaking of new the years some out to of site those new the its longer take things seams here, been over little investments like minor got be and gonna in some some in this founding are bit based the and we has got attract EUMDR we've investment off to location company, pay a and we've XX investment, and need some us talent. since a ago for to building

we're to great a area So that. for moving

introductions, So efforts, quality you're and to next two term, innovation and generation seeing some to system benefit almost the seeing regulatory, the benefit in next commercialization five term, along of longer over product then with you'll which see a those. it's In years, which summary, we're you'll the short immediately the of. mid see

UnidentifiedAnaylst

just, just of far us on commercially? if received competitors any your there? update you've where one that. Just you the Can conversation very the any if then topics give sounds Okay, and And feedback, an have syringe it's excited here, you remind as That's prefilled perfect. It products stands of about me so just anecdotal big that very well. question out for like last you're of quick, side. pre-filled has helpful been can even

Linda Tharby

Okay.

our and I'll I'll market where bring at the down with is right basis just in then customer So start it our competition. to maybe

the market year being about penetration over prefills of just a currently So launched. is X.X%

company XX we that's marketplace. on in is format Hizentra and ml So the only with the think and a are ml, fantastic. prefills X XX prefills Currently the ml

are together convenience we training. a on working the factor. So trying paper white to get talk today about We're to patient

use should time that continue our reduced shows we because there. product customer's in that market clinic both seen move. so quarter advantage next the really pharmacy out We evidence increased have that that hope specialty can the to push preference the overall have in the we of We patients will to that begin prefills. the believe and So to into

if you out at a anybody you of drying that vial. received, market that think outside in at If of look you was right? COVID see You IG about any a format, vaccination up pre-fill prefills, didn't the

pump So the we only think CSL for in get that is will that is prefilled broader date, market And pre-fill are SCIg use there to we with syringe. a time. and approved format over the

So prefills. all we've They three start to of area. but for we're small early pharmaceutical year its here in a that in pretty very with got have working leg it's on really developments off think the the given this closely numbers strategy and in X.X% we market, we five our partners their

Operator

And your Nowak on next the with comes question Craig our Capital. proceed Hallum of Alex question. Please line with

Alex Nowak

to uptake subcue drugs. out the non- expand today things are going of Hizentra plasma Great, good regards starts. on here conversion kind everyone. and on afternoon, just maybe in increase of the new supply that Is then there stay starting for Hoping to the the market with where of market. subcue accelerate IG for patient questions, The a couple to how and

Linda Tharby

Okay.

An indication sales, with that's which double the for pump early were So starts US we we growth digit overall. patient that why our us saw in pumps. so the is maybe start by I'll new marketplace encouraged for

indication. So our being activities our we at, likely that look in market that the marketplace. driven the driving to that a by most us of and is share If great increased we're I in is think and

Alex, doesn't base to therapy makes both a convert because want I IV and take done Regarding on evidence IV what therapy. economic right? shortage, easy out as unpack infusion. really to clinical together do. patient starts already lot, doubling IV We're we're our knows one, it on that, everyone of this converting and lot way natural XXX,XXX might we've a There's patients subcue beginning everyone we is currently just a to a little converting for us to once of conversion, though that it remind get customers in There's but on the conversion work sets and finding for we're over a market. base that difficult there, it is some takes that on shortage XX% existing is hoping a but that our that is from patient longer, that putting for

just with takes grow focused it start new the via and ensuring make new pumps capability Supply do we growth we our our that So this don't patient a to this on ex-US to CSL concerns any in in start But little conversations partners, the some plasma, we with specifically not bit beginning And headway that we're that in reported we adding really area. are and patient point, see new there. concerns. think they're at marketplace. drug

don't long we impact see term supply. major or plasma So of any

Regarding spoke indication QX. be with confident to in on the we'll non-IG, be our label to in our December. We label partners EU that topping quite at about and bit we're [indiscernible] [indiscernible] and we added obviously we our get filed QX are will at in that

So we're hopeful with our the have right that QX. we're filing we and on track by it of end

Alex Nowak

the that takes obviously have Very the puts that's I No, the kind of you did you in to that back to in and guidance the QX, have over issues but out point impact of the channel QX from range there, And kind you include set here the great. QX, understand also you XXXX. some helpful. in XX% you got when growth of Omicron

some prefilled we online, Could get subcue XXXX IG that the are coming the rest subcue there? if, a and to just number IG. year, with the of what curious of growth more of XX% throughout this return here that clear you new if hopefully levers in business sort just kind conversion drugs combine So from syringes, here have you COVID

Linda Tharby

XX% two that great so I us growth there are area. that question get and to Yeah, think levers

the there. by that's and us. one market as one, the kind now, first double IG digits, but grows you but about Omicron encouraged IG market grows biggest it versus gets of digits. going not a the high we is thing it drive The IG the thinking does right? Again right digits, help If so market, QX, we're to to have note double us if the back make that's number QX single going impact, If that's that's market quarter one to

of more reflective our excited one organization in pipeline. we're excited you novel is we into four the revenues thing that's through about. commitments more communicating are about, you. that in we total come make that us quarter agreements The on second of to with not the XXXX, we're the we're All most signed, see deals signed. of that's deliver in number success those will probably therapies A as push The progress our that numbers the that the value and effect over could the we what

Alex Nowak

Okay. makes No, of And kind sense. just… that total

Linda Tharby

the Europe third. is

relative and indications looking to energy haven't in lot at with Europe there. area, in on us that We could invested I a label more at Europe strategic point also coming think this of XXXX push

Alex Nowak

other the office Makes will sense items you New main just in two or are and is going other the then XXXKs Jersey, housekeeping Okay. then is become the of the here, expecting. facilities three, you're eight the that the two what be watching XXXKs headquarters I in running be for? hitting or those new total one indications should here to that future, [indiscernible], three and different you know of we XXXKs mentioned

Linda Tharby

Okay.

will yes. maintain Mahwah, York an headquarters a mitigation in perspective become located in will Chester, we facility facility New our XXXX. extension signed we end question first first, the until have is that the risk New the Jersey from KORU of just It So and

June, start So then close and new facility facility in to production the between expect QX we QX. existing have the in move to

one then because on the Regarding of the and confidential, what two you can see QX And and the of other prefill XXXX. what the XXXKs, talk were already, QX of course [indiscernible] expect we've then to but [indiscernible] see prefill we'll There's probably CSL be they about more I that them in about that I the for some the three about is indications and you coming the first see can't talk are of expanded them spoke was can to all of I right? one going about horizon, were indications. talked

end the introductions that us file by You'll see XXXX. hope of some new from we to product

other that. So and things beyond obviously

to file As know and be Alex, the as soon first you know amongst we team we that something will

Alex Nowak

That update. the sounds Thanks. good. appreciate I

Operator

comes Please the next your Kyle Rose proceed Canaccord And of from question. question with with line Genuity.

UnidentifiedAnalyst

terms for strong just maybe the Kyle. is in questions. on and evening. versus for Congrats US start out novel commercialize of QX one US how within at on as This quarter, shake we online Good the taking novel Gibran begin made of therapies And To did Linda, therapies, the thanks term -- contribution? begins points longer the to the how you maybe the up to pipeline and OUS about maybe following should too, on come EU think contribution?

Linda Tharby

Okay.

I therapies, to So it's therapies have the US deals of right. think to versus make Giron were this specific how novel sure novel I I and questions, exUS, one many want two is

UnidentifiedAnalyst

Correct? Yes.

Linda Tharby

Okay.

global a in our drugs earlier are market development for -- ex-US out one likely And two then initiative And time. So that on was market they're essentially have the see could are question be drug. ex-US for three a phases. how revenues was global. One will were do an second over their product is what but three for registration we in launches, and current breaking

is think our business. of our I was, core of about about domestic XX% today International XX% is core business.

overall time you dramatically both that growing that can changing project with those over we think markets digits. split I between see don't double two

it the think our over represents years therapies about business. five of our where you'll XX% our continue today change of big is X% novel the and expand or to less next overall I represent see than X% business growth

going see to business. we area be that's So biggest expand in our the

UnidentifiedAnalyst

out patient this some know end. to far thus look helpful. I Appreciate in end anything specific to one there Great. That's of CIDP. QX, maybe and did more dynamics And then between the year call the numbers our had maybe you and there, quarter. Linda, but just PIDD What color like alluded from the

Linda Tharby

for was those I the between that don't have I went and difference starts market this But about This the wish overall patient you know the PIDD in I into and numbers. PIDD drug I CIDP. for at do drug -- the overall had market. IG Yeah, in we tell overall growth can of point is numbers CIDP. that terms not X%

UnidentifiedAnalyst

taking question. Appreciate Had the to ask. Fair you enough.

Linda Tharby

Thanks. Great.

Operator

end reached we of call the closed for And Linda have Tharby the back the to question-and-session. remarks. I'll over turn now

Linda Tharby

Great.

close thank I day, all Thank and by our healthy. for And strong particular, the I just investors thank to you stay your for the to a So you in effort year. and XXXX of in to to want fantastic safe great very participation team stay have want end today. a in saying

Operator

this today's And concludes conference.

time. You your Thank line this may for your disconnect you at participation.

KORU Medical Systems (KRMD) 3 Mar 222021 Q4 Earnings call transcript